TL;DR
Get self-care and calm essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Leqembi and Kisunla are FDA-approved antibodies for early symptomatic Alzheimer’s that bind different forms of beta-amyloid and help the immune system clear it. Clinical trials found modest slowing of decline, but how much that changes everyday life remains disputed, and both drugs carry risks of brain swelling and bleeding.
Leqembi and Kisunla, the two anti-amyloid antibodies approved in the United States for Alzheimer’s treatment, bind to different forms of beta-amyloid and help the immune system clear it from the brain. Clinical trials found that both drugs modestly slowed cognitive and functional decline in people with early Alzheimer’s, but they do not restore lost memory, and the size of their benefit in daily life remains debated.
Leqembi (lecanemab) binds to amyloid plaques and smaller beta-amyloid aggregates called protofibrils. Kisunla (donanemab) primarily targets a modified form of beta-amyloid found in established plaques. Both are laboratory-made monoclonal antibodies: they attach to selected targets, after which the immune system helps remove the bound material.
In Leqembi’s phase 3 trial, participants taking the drug declined about 27 percent more slowly over 18 months than participants receiving placebo. In Kisunla’s phase 3 trial, people in the overall study population had a 37 percent lower risk of progressing to the next clinical stage over 76 weeks than those receiving placebo. These are results from different trials and measures, so the figures do not establish that one drug is more effective than the other.
Neither treatment is a cure, and neither reverses memory loss that has already occurred. The source report says both drugs reduced brain amyloid in clinical trials, while researchers continue to study how that reduction relates to changes in symptoms. Anti-amyloid treatment can also increase the risk of brain swelling and bleeding, making the potential benefit-risk balance part of treatment decisions.
What Amyloid Removal Can Change
These medicines act on a feature of Alzheimer’s biology rather than directly relieving symptoms. That makes them different from treatments aimed only at managing symptoms, but the trial results indicate a slowing of decline, not an improvement or recovery. For patients and families, the practical question is whether that average slowing is noticeable enough to matter in daily activities, and whether it justifies treatment risks and demands.
The evidence is still contested. An April 2026 Cochrane review, pooling 17 trials with more than 20,000 participants, concluded that the average cognitive and functional benefits of anti-amyloid antibodies were too small to be clinically meaningful, while finding increased risks of brain swelling and bleeding. Some Alzheimer’s specialists disputed that conclusion, saying the review grouped newer drugs with older antibodies that did not substantially clear amyloid. The disagreement reflects different judgments about evidence and meaningful benefit; it does not change the fact that the medicines’ effects are modest on average.
Alzheimer's monoclonal antibody treatments
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Two Drugs Differ
Monoclonal antibodies are proteins made in a laboratory to recognize and bind a particular target. In Alzheimer’s, Leqembi and Kisunla target beta-amyloid, which can aggregate and form plaques between brain cells. Amyloid plaques are a hallmark associated with Alzheimer’s, though the precise roles of different amyloid forms in cognitive decline are still being studied.
The U.S. Food and Drug Administration approved Leqembi in July 2023, followed by Kisunla in 2024. Both were studied and approved for people in the earliest symptomatic stages of Alzheimer’s, making timely identification of eligible patients relevant. The source report notes that researchers are also investigating antibodies aimed at other targets involved in the disease, including proteins on brain immune cells.
Evidence beyond trials is emerging but has limits. An Eisai-funded study of 177 people who had taken Leqembi for a year reported that 77 percent had not progressed to the next disease stage and 7 percent had moved from early Alzheimer’s to mild cognitive impairment. Because the study had no placebo group, those outcomes cannot show how much stability was caused by the drug rather than other factors or the disease’s course.
“Existing approved drugs offer some benefit for some patients, but there remains a high unmet need for more effective treatments. Sadly, anti-amyloid drugs do not offer this and bring additional risks.”
— Edo Richard, professor of neurology at Radboud University Medical Centre and senior author of the Cochrane review
As an affiliate, we earn on qualifying purchases.
Questions About Benefit and Risk
It remains unclear how much amyloid removal itself explains the modest slowing observed in trials. The source report says newer research suggests that clearing more amyloid does not necessarily produce greater slowing of cognitive decline. Researchers are also still assessing whether trial-level differences translate into meaningful changes in everyday life for individual patients.
Longer-term effects are not settled. Alzheimer’s progresses slowly, and the reported real-world observations cover relatively short periods; the Leqembi study lacked a placebo comparison. The source material does not provide a full account of eligibility criteria, monitoring protocols, or how individual medical circumstances affect decisions. Those details should be checked with clinicians and current prescribing information.
brain health supplements for Alzheimer's
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Longer Follow-Up and Patient Selection
Researchers will need longer follow-up and stronger real-world comparisons to clarify how durable the effects are and which patients are most likely to benefit. The source report says 2026 real-world data continued to suggest that many patients remain stable during treatment, while cautioning that short observation periods make the drugs’ longer-term impact difficult to measure.
For now, the evidence supports a narrow description: the medicines can modestly slow decline in some people with early symptomatic Alzheimer’s, while carrying risks that need to be weighed in care decisions. Further evidence on long-term outcomes, patient selection and everyday function will help clarify how that balance looks outside clinical trials.
Alzheimer's disease cognitive decline therapy
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
How do Leqembi and Kisunla work?
Both are monoclonal antibodies that bind to beta-amyloid and help the immune system clear it from the brain. Leqembi targets plaques and protofibrils, while Kisunla primarily targets a modified form of amyloid found in established plaques.
Do either of the drugs cure Alzheimer’s or restore lost memory?
No. The source report says neither drug is a cure or restores memory already lost. Trial evidence indicates modest slowing of cognitive and functional decline in people with early Alzheimer’s.
How much did the drugs slow decline in trials?
In its phase 3 trial, Leqembi was associated with about 27 percent slower decline over 18 months than placebo. In Kisunla’s phase 3 trial, participants in the overall study population had a 37 percent lower risk of progressing to the next clinical stage over 76 weeks than those receiving placebo. The trials used different measures, so the numbers are not a direct comparison.
What are the main concerns about these treatments?
The source report identifies increased risks of brain swelling and bleeding. Researchers and specialists also disagree about whether the average benefit is large enough to be clinically meaningful. Patients should discuss risks and treatment decisions with a qualified health professional.
Who were the drugs studied and approved for?
The source report says Leqembi and Kisunla were studied and approved for people in the earliest symptomatic stages of Alzheimer’s. Individual eligibility depends on clinical assessment; the supplied report does not give full criteria.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
